ClinicalTrials.gg
RecruitingNCT07516366Updated Nov 20, 2026

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

A Phase 2 interventional study of Balstilimab and Biospecimen Collection in Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 and Stage III Renal Cell Cancer AJCC v8, sponsored by National Cancer Institute (NCI). Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 20266 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 116 studies in Carcinoma, Renal Cell by National Cancer Institute (NCI) — 9 open to participants now, 24 under way, 4 of them phase 3. Carcinoma, Renal Cell · National Cancer Institute (NCI).

Planned enrollment
80th of 104
16 · median 39
Started
2027
with 1 other
Phase 2
58 of 116
4 open now
Primary completion
2028-12
later than 18 of 22 live
Registered
115th of 116
by date

Among the 116 studies in Carcinoma, Renal Cell by National Cancer Institute (NCI), this one is the 80th largest by planned enrollment of the 104 interventional ones that give a count, is one of 2 that started in 2027, is one of 58 in phase 2, reaches primary completion later than 18 of the 22 other live ones, and was the 115th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

9 of the 116 studies in Carcinoma, Renal Cell by National Cancer Institute (NCI) are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Carcinoma, Renal Cell by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase II trial tests the effect of botensilimab and balstilimab before surgery (neoadjuvant) in treating patients with high-risk clear cell renal cell cancer that has not spread from where it first started to other areas of the body (non-metastatic). The current standard treatment for patients with non-metastatic clear cell renal cell cancer may include surgery to completely remove the tumor. This typically involves removing the kidney or part of the kidney (nephrectomy). Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving neoadjuvant botensilimab and balstilimab may be safe, tolerable, and/or effective in treating patients with high-risk non-metastatic clear cell renal cell cancer before undergoing a nephrectomy.

Read the detailed description

PRIMARY OBJECTIVE:

I. To investigate the safety and feasibility of neoadjuvant botensilimab and balstilimab in high-risk (T2a-T4Nany M0 or Tany N1M0) non-metastatic clear cell renal cell carcinoma via assessment of ability to undergo timely nephrectomy.

SECONDARY OBJECTIVES:

I. To investigate the safety of neoadjuvant botensilimab and balstilimab in high-risk (T2a-T4Nany M0 or Tany N1M0) non-metastatic clear cell renal cell carcinoma via assessment of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

II. To investigate the surgical morbidity of neoadjuvant botensilimab and balstilimab in high-risk (T2a-T4Nany M0 or Tany N1M0) non-metastatic clear cell renal cell carcinoma via assessment of Clavien-Dindo classification of surgical morbidity, respectively.

III. To evaluate the objective response rate (ORR) of the primary tumor following neoadjuvant botensilimab and balstilimab per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, defined as complete response (CR) or partial response (PR), any time after starting treatment.

IV. To evaluate the proportion of patients achieving a major pathologic response (defined as \< 10% of viable tumor in the tumor bed) and a partial pathologic response (defined as less than 50% of the viable tumor in tumor bed), through centralized pathology review.

V. To evaluate disease-free survival (DFS), rates of distant metastasis and local recurrence following neoadjuvant botensilimab and balstilimab in high-risk clear cell renal cell carcinoma.

EXPLORATORY OBJECTIVES:

I. To investigate the relationship between tumor cell programmed death ligand 1 (PD-L1) expression, CD8+ T-cell infiltration in the tumor microenvironment, and clinical outcomes.

II. To examine the association of specific genetic alterations (Braun et al., 2020) identified through whole-exome sequencing (WES) and transcriptional clusters (Motzer et al., 2020) identified via ribonucleic acid (RNA) sequencing, in relation to clinical outcomes.

III. To characterize the phenotypes of circulating T cells, cytokines, chemokines, and angiokines at baseline and after neoadjuvant therapy to evaluate their association with therapeutic efficacy and clinical response.

IV. To assess circulating tumor deoxyribonucleic acid (DNA) (ctDNA) to detect minimal residual disease (MRD) as a marker of therapeutic response and post-nephrectomy clinical outcomes.

V. To investigate the correlation between circulating levels of soluble KIM-1 and clinical outcomes, including therapeutic response and post-nephrectomy clinical outcomes.

OUTLINE:

Patients receive botensilimab intravenously (IV) over 30 minutes on day 1 of weeks 1 and 7 and balstilimab IV over 30 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11 in the absence of disease progression or unacceptable toxicity. Patients undergo nephrectomy 12-16 weeks from the initiation of neoadjuvant therapy. Additionally, patients undergo blood sample collection and computed tomography (CT) throughout the study.

After completion of study treatment, patients are followed every 3 months for up to 1 year post-nephrectomy.

03

Conditions studied

  • Clear Cell Renal Cell Carcinoma
  • Stage II Renal Cell Cancer AJCC v8
  • Stage III Renal Cell Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have -confirmed, non-, high-risk renal cell carcinoma (RCC) with a clear cell component, defined as clinical stage T2N0, T3N0, T4N0, or any T stage with N1 disease (i.e., T2a-T4NanyM0 or TanyN1M0), and no evidence of metastatic disease
  • Participants with resectable RCC are eligible, including those who have previously undergone surgical resection for RCC and subsequently developed resectable recurrent disease. Patients must be candidates for further curative-intent surgical resection. Prior systemic therapy for RCC (including VEGF-targeted therapy, , HIF-2α inhibitors, or other systemic anticancer therapies) is not allowed
  • Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of botensilimab in combination with balstilimab in patients \< 18 years of age, children are excluded from this study
  • (ECOG) performance status ≤ 2 (or ≥ 60%)
  • Patients must be considered suitable for curative-intent surgical resection of RCC, including radical or partial nephrectomy, as determined by the urology team and the treating physician according to standard clinical guidelines
  • ≥ 1,000/mcL
  • ≥ 100,000/mcL
  • Total ≤ 1.5 x institutional (ULN)
  • (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x institutional ULN
  • (GFR) 50 mL/min (calculated using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation)
  • (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial. Also including a prior history of renal cell carcinoma
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients should be class II or better
  • Patients must be scheduled to undergo either partial or radical nephrectomy as part of treatment plan
  • The effects of botensilimab and balstilimab on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and 4 months after completion of treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of botensilimab and balstilimab administration. All patients of childbearing potential must undergo a blood or urine pregnancy test within 14 days prior to receiving the first dose of botensilimab and balstilimab to confirm they are not pregnant. If dosing is delayed beyond this window, the pregnancy test must be repeated to ensure results remain current
  • Ability to understand and the willingness to sign a written document. Legally authorized representatives may sign and give informed consent on behalf of study participants
  • Availability of pre-treatment archival slides or tissue blocks is required for inclusion in the study

Exclusion criteria

Exclusion Criteria:

  • Patients who have suspected or proven renal cell carcinoma
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
  • Patients who are receiving any other agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to botensilimab or balstilimab
  • Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous
  • Pregnant women are excluded from this study because botensilimab and balstilimab are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with botensilimab or balstilimab, breastfeeding should be discontinued if the mother is treated with botensilimab or balstilimab
  • Patients without a clear cell component in their baseline kidney or non-clear cell renal cell carcinoma (RCC) are excluded from this study
  • Patients who have received prior treatment with an , anti-programmed cell death protein ligand 1 (PD-L1), anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
  • Patients who have undergone major surgery within 28 days prior to the start of the study
  • Patients with any active or recent history of a known or suspected disease or recent history of a syndrome that required systemic (> 10 mg daily prednisone equivalent) or medications within 14 days prior to first dose of study drug; the exception would be for syndromes which would not be expected to recur in the absence of an external trigger. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
  • Patients with vitiligo or type I diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement are permitted to enroll
  • Patients with a baseline interval (Fridericia's corrected QT interval [QTcF]) > 480 ms on screening (ECG), a history of congenital long QT syndrome, or cardiac arrhythmias will be excluded
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Treatment (botensilimab, balstilimab)

    Patients receive botensilimab IV over 30 minutes on day 1 of weeks 1 and 7 and balstilimab IV over 30 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11 in the absence of disease progression or unacceptable toxicity. Patients undergo nephrectomy 12-16 weeks from the initiation of neoadjuvant therapy. Additionally, patients undergo blood sample collection and CT throughout the study.

    Biological: Balstilimab · Procedure: Biospecimen Collection · Biological: Botensilimab · Procedure: Computed Tomography · Procedure: Nephrectomy · Other: Questionnaire Administration

Interventions

  • BiologicalBalstilimab

    Given IV

    Also known as: AGEN 2034, AGEN-2034, AGEN2034

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • BiologicalBotensilimab

    Given IV

    Also known as: AGEN 1181, AGEN-1181, AGEN1181, Anti-CTLA-4 Monoclonal Antibody AGEN1181

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureNephrectomy

    Undergo nephrectomy

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Proportion of patients successfully completing neoadjuvant treatment and undergoing planned definitive surgical resection of primary tumor (radical or partial nephrectomy) without significant treatment related delays

    The intervention will be considered feasible if at least 80% of enrolled patients (13 out of 16) successfully undergo planned radical or partial nephrectomy following treatment.

    Time frame: Up to 1 year post-surgery

  2. Incidence and severity of treatment-related adverse events

    Will be analyzed descriptively using frequencies and proportions, stratified by severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 30 days after last dose of study treatment

  3. Incidence and severity of surgical complications

    Will be summarized using the Clavien-Dindo Classification.

    Time frame: Up to 30 days after surgery

Secondary outcomes

  1. Objective response rate (ORR)

    Will be defined as the proportion of patients achieving a complete response or partial response of the primary tumor as defined by Response Evaluation Criteria for Solid Tumors 1.1 criteria. ORR will be summarized as a proportion with a 95% confidence interval (CI) using the Clopper-Pearson method (exact binomial CIs), and analyses conducted on both the intention-to-treat and per-protocol populations.

    Time frame: After neoadjuvant treatment, assessed up to 1 year post-nephrectomy

  2. Major pathologic response (MPR) rate

    Will be defined as the proportion of patients with \< 10% viable tumor cells. MPR rate will be determined through centralized pathology review of the surgical specimen, summarized as proportions with 95% CIs using Clopper-Pearson method, and a descriptive comparison between response categories will be presented.

    Time frame: Up to 1 year post-surgery

  3. Partial pathologic rate (PPR) rate

    Will be defined as the proportion of patients with \< 50% viable tumor cells in the tumor bed of the resected specimen, will be assessed. PPR rate will be determined through centralized pathology review of the surgical specimen, summarized as proportions with 95% CIs using Clopper-Pearson method, and a descriptive comparison between response categories will be presented.

    Time frame: Up to 1 year post-surgery

  4. Rates of distant metastasis

    Will be defined as proportion of patients experiencing distant metastatic disease. Will be summarized as proportions with 95% CIs.

    Time frame: Up to 1 year post-surgery

  5. Rates of local recurrence

    Will be defined as proportion of patients experiencing local recurrence after treatment. Will be summarized as proportions with 95% CIs.

    Time frame: Up to 1 year post-surgery

  6. Disease-free survival (DFS)

    DFS will be analyzed using the Kaplan-Meier method for medians and survival curves, with subgroup comparisons by log-rank tests and hazard ratios estimated using Cox proportional hazards models.

    Time frame: From surgery to the first documented evidence of disease recurrence (local, regional, or distant metastasis) or death from any cause, assessed up to 1 year

Other outcomes

  1. Changes in immune biomarkers

    Single-cell ribonucleic acid sequencing will be performed on tumor tissue to evaluate changes within the tumor microenvironment. Will be analyzed using paired t-tests or Wilcoxon signed-rank tests for non-normally distributed data, and multivariable models will be used to explore correlations between these changes and clinical endpoints (e.g., ORR, MPR).

    Time frame: At baseline and after treatment, assessed up to 1 year

  2. Systemic immune activation markers

    Peripheral blood mononuclear cell analysis will be conducted. Changes will be analyzed using paired t-tests or Wilcoxon signed-rank tests for non-normally distributed data, and multivariable models will be used to explore correlations between these changes and clinical endpoints (e.g., ORR, MPR).

    Time frame: At baseline and after treatment, assessed up to 1 year

  3. T-cell clonality and diversity

    T-cell receptor sequencing will be used to evaluate tumor and blood samples. Data will be summarized descriptively, with changes in clonality indices assessed using paired statistical tests, while associations between TCR clonality and clinical outcomes (e.g., ORR, DFS) will be explored using logistic or Cox regression models.

    Time frame: At pre and post treatment, assessed up to 1 year

  4. Immune cell subset analysis

    Immunofluorescence immunohistochemistry will be employed to assess immune cell subsets, including CD8+, CD4+, and Treg populations, within the tumor microenvironment. Data will be summarized descriptively, with changes assessed using paired statistical tests, while associations between immune cell subsets and clinical outcomes (e.g., ORR, DFS) will be explored using logistic or Cox regression models.

    Time frame: At pre and post treatment, assessed up to 1 year

  5. Soluble biomarkers, including KIM-1, and other renal injury markers

    Will be measured in blood samples. Will be analyzed using paired t-tests or non-parametric equivalents.

    Time frame: At baseline, before surgery, and post-treatment, will be assessed up to 1 year

  6. Circulating tumor deoxyribonucleic acid levels

    Will be analyzed to assess dynamic changes and their correlation with treatment response and disease progression. Linear mixed-effects models for longitudinal changes, and their correlations with clinical outcomes (e.g., DFS, ORR, MPR) will be explored using Spearman or Pearson correlation coefficients.

    Time frame: At pre-and post-treatment, assessed up to 1 year

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Dec 2028, 19 months later.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 19 months is below that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 8, 2026
StartEst.
May 17, 2027
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 1 site removed
Show 6 added (6 United States)
  • University of Oklahoma Health Sciences Center · Oklahoma City, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, United States
  • University of Virginia Cancer Center · Charlottesville, United States
  • UF Health Cancer Institute - Gainesville · Gainesville, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center · Baltimore, United States
Show 1 removed
  • Yale University Cancer Center LAO · New Haven, United States
across 6 updates, Oct 8, 2026 – Nov 20, 2026
Show all 6 updates
  1. Nov 20, 2026
    1 site added
    Show site
    • Johns Hopkins University/Sidney Kimmel Cancer Center · Baltimore, United States
  2. Oct 21, 2026
    1 site added
    Show site
    • UF Health Cancer Institute - Gainesville · Gainesville, United States
  3. Oct 15, 2026
    1 site added
    Show site
    • University of Virginia Cancer Center · Charlottesville, United States
  4. Oct 13, 2026
    2 sites added
    Show 2 added (2 United States)
    • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, United States
    • UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, United States
  5. Oct 9, 2026
    1 site removed
    Show 1 removed
    • Yale University Cancer Center LAO · New Haven, United States
  6. Oct 8, 2026
    1 site added
    Show site
    • University of Oklahoma Health Sciences Center · Oklahoma City, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07516366
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
May 17, 2027 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Adanma Anji Ayanambakkam Attanathi
principal investigator · Yale University Cancer Center LAO

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Balstilimab · Botensilimab

Start the discussion